Literature DB >> 26432329

Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.

Yanwei Ye1,2, Dongbao Jiang3,4, Jingjing Li4,5, Min Wang6, Chao Han7, Xiefu Zhang3,4, Chunlin Zhao3,4, Jianguo Wen4, Quancheng Kan4,5.   

Abstract

To clarify the role of fibroblast growth factor receptor 4 (FGFR4) in gastric cancer (GC) and explore the therapeutic value of BGJ398 targeted to FGFR4. We constructed lentivirus vectors to stably knockdown FGFR4 expression in GC cells. Function assays in vitro and in vivo, treated with 5-fluorouracil (5-Fu) and BGJ398, were performed to study the change of biological behaviors of GC cells and related mechanism. The proliferation and invasive ability of HGC27 and MKN45 significantly decreased while the apoptosis rate of GC cells obviously increased in shRNA group (P < 0.05). The expressions of Bcl-xl, FLIP, PCNA, vimentin, p-erk, and p-STAT3 significantly reduced while the expressions of caspase-3 and E-cadherin markly enhanced in shRNA group. The proliferation abilities of GC cells were more significantly inhibited by the combination of BGJ398 and 5-Fu in shRNA group (P < 0.05). Compared to negative control (NC), the single and combination of 5-Fu and BGJ398 all significantly increased the apoptosis rate of GC cells, especially in the combination group (P < 0.01). The single and combination of 5-Fu and BGJ398 decreased the expressions of PCNA, Bcl-xl, and FLIP while increased the expression of caspase-3 in GC cells, especially in shRNA groups. Furthermore, knockdown of FGFR4 expression might prevent the growth of GC in vivo. Silencing of FGFR4 expression could weaken the invasive ability, increase the apoptosis rate, and decrease the proliferation ability of GC cells in vitro and in vivo. Furthermore, the combination of 5-Fu and BGJ398 had synergy in inhibiting the proliferation ability and increasing apoptosis rate of GC cells, directing a new target drug in GC.

Entities:  

Keywords:  5-Fluorouracil; BGJ398; Fibroblast growth factor receptor 4; Gastric cancer; shRNA

Mesh:

Substances:

Year:  2015        PMID: 26432329     DOI: 10.1007/s13277-015-4100-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

1.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

2.  Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.

Authors:  Masaru Katoh
Journal:  Expert Rev Anticancer Ther       Date:  2010-09       Impact factor: 4.512

3.  The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.

Authors:  Yanwei Ye; Yingqiang Shi; Ye Zhou; Chunyan Du; Chunmeng Wang; Heqin Zhan; Biqiang Zheng; Xi Cao; Meng-Hong Sun; Hong Fu
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

4.  FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.

Authors:  Fang Li; Hung Huynh; Xiaoyan Li; David A Ruddy; Youzhen Wang; Richard Ong; Pierce Chow; Shumei Qiu; Angela Tam; Daniel P Rakiec; Robert Schlegel; John E Monahan; Alan Huang
Journal:  Cancer Discov       Date:  2015-02-11       Impact factor: 39.397

5.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

6.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

7.  The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients.

Authors:  Yan-Wei Ye; Xiefu Zhang; Ye Zhou; Jianghong Wu; Chunlin Zhao; Lin Yuan; Guojun Wang; Chunyan Du; Chunmeng Wang; Yingqiang Shi
Journal:  J Surg Oncol       Date:  2012-05-14       Impact factor: 3.454

8.  The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Authors:  Kristine A Drafahl; Christopher W McAndrew; April N Meyer; Martin Haas; Daniel J Donoghue
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

9.  Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Authors:  R C Turkington; D B Longley; W L Allen; L Stevenson; K McLaughlin; P D Dunne; J K Blayney; M Salto-Tellez; S Van Schaeybroeck; P G Johnston
Journal:  Cell Death Dis       Date:  2014-02-06       Impact factor: 8.469

10.  Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  F Lordick; B Luber; S Lorenzen; S Hegewisch-Becker; G Folprecht; E Wöll; T Decker; E Endlicher; N Röthling; T Schuster; G Keller; F Fend; C Peschel
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more
  6 in total

1.  Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.

Authors:  Masami Yamamoto; Sachiyo Nomura; Akihiro Hosoi; Koji Nagaoka; Tamaki Iino; Tomohiko Yasuda; Tomoko Saito; Hirokazu Matsushita; Eiji Uchida; Yasuyuki Seto; James R Goldenring; Kazuhiko Kakimi; Masae Tatematsu; Tetsuya Tsukamoto
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716

2.  Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway.

Authors:  Caixia An; Hailong Li; Xueyan Zhang; Jing Wang; Yi Qiang; Xinhua Ye; Qiang Li; Quanlin Guan; Yongning Zhou
Journal:  Int J Oncol       Date:  2019-02-18       Impact factor: 5.650

3.  FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.

Authors:  Yanwei Ye; Jie Li; Dongbao Jiang; Jingjing Li; Chuangfeng Xiao; Yingze Li; Chao Han; Chunlin Zhao
Journal:  Cancer Res Treat       Date:  2020-05-25       Impact factor: 4.679

4.  Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.

Authors:  Kai Hung Tiong; Boon Shing Tan; Heng Lungh Choo; Felicia Fei-Lei Chung; Ling-Wei Hii; Si Hoey Tan; Nelson Tze Woei Khor; Shew Fung Wong; Sze-Jia See; Yuen-Fen Tan; Rozita Rosli; Soon-Keng Cheong; Chee-Onn Leong
Journal:  Oncotarget       Date:  2016-09-06

5.  Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.

Authors:  Charu Sonkar; Tarun Verma; Debi Chatterji; Ajay Kumar Jain; Hem Chandra Jha
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

Review 6.  FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Authors:  Csongor G Lengyel; Sadaqat Hussain; Andreas Seeber; Sara Jamil Nidhamalddin; Dario Trapani; Baker S Habeeb; Essam Elfaham; Syed Ayub Mazher; Fahmi Seid; Shah Z Khan; Khalid El Bairi; Andrew Odhiambo; Sara C Altuna; Angelica Petrillo
Journal:  Life (Basel)       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.